Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
TScan Therapeutics, Inc. (TCRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/15/2023 |
4
| BARBERICH TIMOTHY J (Director) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $2.66, valued at
$93.1k
|
|
| 06/15/2023 |
4
| Barton Debora (Chief Medical Officer) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 430,000 options to buy
@ $2.49, valued at
$1.1M
|
|
| 06/15/2023 |
4
| Dorton Katina (Director) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $2.66, valued at
$93.1k
|
|
| 06/15/2023 |
4
| Gruia Gabriela (Director) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 35,000 options to buy
@ $2.66, valued at
$93.1k
|
|
| 06/15/2023 |
4
| Klencke Barbara (Director) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 36,524 options to buy
@ $2.66, valued at
$97.2k
|
|
| 06/15/2023 |
4
| Silver Brian M. (CFO) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 632,500 options to buy
@ $2.49, valued at
$1.6M
|
|
| 06/15/2023 |
4
| MacBeath Gavin (CEO) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 1,121,300 options to buy
@ $2.49, valued at
$2.8M
|
|
| 06/15/2023 |
4
| ZDRAVESKI ZORAN (Chief Legal Officer) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Granted 430,000 options to buy
@ $2.49, valued at
$1.1M
|
|
| 06/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/12/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 9.4% stake in TScan Therapeutics, Inc. |
| 06/08/2023 |
SC 13G/A
| BlackRock Inc. reports a 3% stake in TScan Therapeutics, Inc. |
| 06/06/2023 |
4
| BARBERICH TIMOTHY J (Director) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Bought 37,880 shares
@ $2.6284, valued at
$99.6k
|
|
| 06/02/2023 |
4
| Lynx1 Capital Management LP (10% Owner) has filed a Form 4 on TScan Therapeutics, Inc.|
Txns:
| Sold 10,000 shares
@ $2.5148, valued at
$25.1k
Sold 15,000 shares
@ $2.5201, valued at
$37.8k
Sold 400 shares
@ $2.5075, valued at
$1k
|
|
| 06/02/2023 |
3
| Lynx1 Capital Management LP (10% Owner) has filed a Form 3 on TScan Therapeutics, Inc. |
| 06/02/2023 |
SC 13G
| Lynx1 Capital Management LP reports a 12.2% stake in TScan Therapeutics, Inc. |
| 05/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/31/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors WALTHAM, Mass., May 24 , 2023 — TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, today announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer of TScan and as a Class I Director of its Board, each effective as of May 24, 2023. Dr. MacBeath, has been serving as acting CEO since March 2023. Dr. MacBeath joined TScan in 2018 and has developed and advanced the Company's scientific platform and clinical programs. Since his appointment as acting CEO, the Company has made great progress across both..." |
|
| 05/26/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 05/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/17/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/16/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/16/2023 |
AW
| Form AW - Amendment Withdrawal Request: |
| 05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
|
|
|